Iasodopa

Fluorodopa, the active ingredient in Iasodopa, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables PET visualization of dopamine synthesis pathways and is employed primarily in the assessment of dopaminergic function in neurological disorders. Approved in the European Union, the product conforms to strict radiopharmacy standards and is distributed under controlled conditions to ensure radiochemical purity.

GNH USA supplies Iasodopa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic centres and research institutions worldwide, with validated cold‑chain logistics and regulatory support.

Iasodopa is used in PET imaging to evaluate dopaminergic pathways and related movement disorders.

- Parkinsonian syndromes: enables quantitative assessment of presynaptic dopaminergic function to aid diagnosis and disease staging. - Parkinson's disease: provides visualisation of dopamine synthesis deficits, supporting clinical decision‑making and monitoring of progression. - Atypical parkinsonism: helps differentiate between multiple system atrophy, progressive supranuclear palsy and other disorders by comparing tracer uptake patterns. - Movement disorder evaluation: assists in the work‑up of tremor, dystonia and bradykinesia when the underlying cause is uncertain. - Clinical research: serves as a biomarker for trials of neuroprotective agents targeting dopamine pathways.

Fluorodopa is generally well tolerated, but adverse reactions can occur following intravenous administration.

Common Side Effects: - Nausea: mild transient feeling of nausea during or shortly after injection. - Headache: mild to moderate headache reported in some patients. - Injection site pain: brief discomfort at the venipuncture site. - Transient flushing: brief skin flushing or warmth. - Dizziness: mild dizziness or light‑headedness. - Mild hypotension: temporary drop in blood pressure without clinical significance.

Serious or Rare Side Effects: - Allergic reaction: urticaria, rash or anaphylaxis requiring immediate medical attention. - Severe hypotension: marked blood pressure fall leading to syncope. - Seizure: rare occurrence of seizure activity post‑administration. - Radiation‑induced tissue injury: localized tissue damage from high radioactivity exposure. - Cardiac arrhythmia: rare abnormal heart rhythm events. - Pulmonary embolism: extremely rare clot formation related to injection.

Prior to using Iasodopa, clinicians should consider several precautionary measures to ensure patient safety and optimal imaging results. - Pregnancy: safety not established; avoid use unless benefits outweigh potential risks. - Breastfeeding: unknown excretion in milk; consider discontinuation during treatment. - Renal impairment: adjust protocol as reduced clearance may affect tracer distribution. - Radiation exposure: limit repeat scans and adhere to ALARA principle to minimize cumulative dose. - Contraindications: do not administer to patients with known hypersensitivity to fluorodopa or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fluorodopa’s tracer uptake can be altered by drugs that affect dopaminergic metabolism or compete for transport mechanisms.

Major Interactions (Avoid): - MAO inhibitors: increase intracellular catecholamine levels, potentially distorting PET quantification. - COMT inhibitors: modify peripheral metabolism of fluorodopa, affecting brain availability. - Dopamine antagonists (antipsychotics): block dopamine receptors, reducing tracer uptake and image accuracy. - Levodopa therapy: competitive substrate for aromatic L‑amino‑acid decarboxylase, leading to reduced fluorodopamine formation. - Other PET tracers: concurrent administration may cause cross‑interference and inaccurate results.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: modest influence on central monoamine pathways that could slightly affect tracer kinetics. - Antihypertensive